A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
Health Arecor and Sequel to Co-Develop Next-Generation Insulin DeliveryHealthradar27. September 2025 What You Should Know: – Arecor Therapeutics, a biopharmaceutical company specializing in drug development and delivery, has announced two major…
Health Qventus Launches AI Solution Factory to Co-Develop AI Assistants for HospitalsHealthradar19. September 2025 What You Should Know: – Qventus, a provider of AI-powered solutions for hospitals, has announced the AI Solution Factory at…
